A, F., C, T., H, S., M, D., W, Z., L, P., . . . W, J. (2021). An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies. Clinical and translational medicine, 11(11), e572. https://doi.org/10.1002/ctm2.572
Chicago Style (17th ed.) CitationA, Findlay, et al. "An Activity-based Bioprobe Differentiates a Novel Small Molecule Inhibitor from a LOXL2 Antibody and Provides Renewed Promise for Anti-fibrotic Therapeutic Strategies." Clinical and Translational Medicine 11, no. 11 (2021): e572. https://doi.org/10.1002/ctm2.572.
MLA (9th ed.) CitationA, Findlay, et al. "An Activity-based Bioprobe Differentiates a Novel Small Molecule Inhibitor from a LOXL2 Antibody and Provides Renewed Promise for Anti-fibrotic Therapeutic Strategies." Clinical and Translational Medicine, vol. 11, no. 11, 2021, p. e572, https://doi.org/10.1002/ctm2.572.
